-
Nkarta Therapeutics NASDAQ:NKTX Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off the shelf natural killer (NK) cell therapies for cancer. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies, Nkarta is building a pipeline of cell therapy candidates generated by efficient manufacturing processes, which are engineered to enhance tumor targeting and improve persistence for sustained activity in the body.
Location: | Website: www.nkartatx.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-25.42M
Cash
283.1M
Avg Qtr Burn
-24.57M
Short % of Float
24.52%
Insider Ownership
5.26%
Institutional Own.
99.87%
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NKX019 (CAR NK cell therapy) Details Autoimmune disease, Scleroderma, Systemic sclerosis, Idiopathic inflammatory myopathy / myositis, ANCA-Associated Vasculitis | Phase 1 Data readout | |
NKX019 (CAR NK cell therapy) Details Systemic lupus erythematosus, Autoimmune disease | Phase 1 Data readout | |
NKX019 (CAR NK cell therapy) Details B-cell malignancies, Non-Hodgkin lymphoma, B-cell lymphoma | Phase 1 Data readout | |
NKX019 (CAR NK cell therapy) Details Lupus nephritis, Autoimmune disease | Phase 1 Update | |
NKX101 (CAR-T targeting NKG2D) Details Bone marrow disorder, Acute myeloid leukemia, Cancer, Myelodysplastic syndrome | Phase 1 Update | |
NKX019 Details Myasthenia gravis | Phase 1 Initiation |